

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously presented): A method of treating osteoarthritis in a human in need thereof comprising orally administering to said human a pharmaceutical composition comprising between 0.4 and 1.2 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

Claims 2-5. (Canceled)

Claim 6. (Previously Presented): The method according to claim 1, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.

Claims 7-8. (Canceled)

Claim 9. (Previously Presented): The method according to claim 1, wherein the delivery agent is a disodium salt of 5-CNAC, a disodium salt of SNAD or a disodium salt of SNAC.

Claim 10. (Previously Presented): The method according to claim 9, wherein the delivery agent is in micronized form.

Claims 11-16. (Canceled)

Claim 17. (Withdrawn): A pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim 18. (Withdrawn): A pharmaceutical combination comprising:

- a) between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof, and
- b) a bone resorption inhibitor, bone forming drug or pain reducing agent.

Claims 19-23. (Canceled)

Claim 24. (Previously Presented): The method according to claim 1, wherein the pharmaceutical composition comprises between 0.8 and 1.2 mg of salmon calcitonin.

Claim 25. (Previously Presented): The method according to claim 24, wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 26. (Previously Presented): The method according to claim 25, wherein the delivery agent is a disodium salt of 5-CNAC.

Claim 27. (Previously Presented): The method according to claim 24, wherein the pharmaceutical composition comprises about 1 mg of salmon calcitonin.

Claim 28. (Previously Presented): The method according to claim 27, wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 29. (Previously Presented): The method according to claim 28, wherein the delivery agent is a disodium salt of 5-CNAC.

Claim 30. (New): A method of preserving and stimulating cartilage in a human having osteoarthritis comprising orally administering to said human a pharmaceutical composition comprising between 0.4 and 1.2 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof.